Inari Medical, Inc. ((NARI)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The PEERLESS II Study, officially titled ‘PEERLESS II: RCT of FlowTriever vs. Anticoagulation Alone in Pulmonary Embolism,’ is a prospective, multicenter, randomized controlled trial. It aims to compare the effectiveness of the FlowTriever System combined with anticoagulation to anticoagulation alone in treating intermediate-risk acute pulmonary embolism (PE). This study is significant as it could potentially offer a more effective treatment option for PE, impacting patient outcomes and clinical practices.
The study tests two interventions: the FlowTriever System, a mechanical thrombectomy device designed to remove blood clots, and standard anticoagulation medications, which prevent blood clotting. The FlowTriever System is intended to provide a more direct and immediate solution to clot removal compared to traditional anticoagulation therapy.
The study design is interventional with a randomized allocation and a parallel intervention model. There is no masking involved, meaning all participants and researchers know which treatment is being administered. The primary purpose of the study is treatment-focused, aiming to assess the efficacy of the FlowTriever System in comparison to standard anticoagulation therapy.
The study began on November 17, 2023, and is currently recruiting participants. The primary completion and estimated study completion dates have not been specified, but the last update was submitted on August 14, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might be available.
The outcome of this study could significantly impact Inari Medical’s stock performance and investor sentiment. A positive result may enhance the company’s market position by validating the FlowTriever System as a superior treatment for PE. This could also influence the competitive landscape, prompting other companies to innovate or improve their offerings in the PE treatment market.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.